for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Apellis Pharmaceuticals Inc

APLS.OQ

Latest Trade

26.48USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

11.45

 - 

33.18

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.48
Open
--
Volume
--
3M AVG Volume
10.88
Today's High
--
Today's Low
--
52 Week High
33.18
52 Week Low
11.45
Shares Out (MIL)
63.70
Market Cap (MIL)
1,680.29
Forward P/E
-7.05
Dividend (Yield %)
--

Latest Developments

More

Apellis Pharmaceuticals Says Currently Enrolling Two Global Confirmatory Phase 3 Studies For Patients With GA

Apellis Pharmaceuticals Announces Pricing Of Offering Of Convertible Senior Notes

Apellis Pharmaceuticals Announces Proposed Private Offering Of $200 Mln Of Convertible Senior Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Industry

Biotechnology & Drugs

Contact Info

6400 Westwind Way Ste a

+1.502.2414114

http://apellis.com/

Executive Leadership

Gerald L. Chan

Independent Chairman of the Board

Cedric Francois

President, Chief Executive Officer, Co-Founder, Director

Pascal Deschatelets

Co-Founder, Chief Operating Officer

Timothy Sullivan

Chief Financial Officer, Treasurer

Thomas Lackner

Senior Vice President, Head of Europe

Key Stats

1.57 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.670

2018

-2.340

2019(E)

-3.744
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
10.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.21
LT Debt To Equity (MRQ)
4.21
Return on Investment (TTM)
-72.20
Return on Equity (TTM)
-66.53

Latest News

Latest News

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up